Bright Minds Biosciences Inc.

DRUG

CA10919W4056

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 20:35:00 23/01/2026 GMT			5-day change	1st Jan Change
120.13 ^CAD	-3.19%		-2.25%	+8.78%

01-09	Bright Minds Biosciences Closes its US$175 Million Public Offering	MT
01-09	Bright Minds Biosciences Closes $175.1 Million Stock Offering	MT

Bright Minds Biosciences Inc.(NasdaqCM:DRUG) added to Russell 3000E Index

Published on 06/30/2025 at 03:26 am BST

S&P Capital IQ

BRIGHT MINDS BIOSCIENCES INC.

-3.19%

RUSSELL 3000

-0.11%

Bright Minds Biosciences Inc.(NasdaqCM:DRUG) added to Russell 3000E Index

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	BRIGHT MINDS BIOSCIENCES INC.	120.13CAD	-3.19%	-2.25%	851M
	RUSSELL 3000	3,940.22PTS	-0.11%	-0.36%	-

Latest news about Bright Minds Biosciences Inc.

01-09	Bright Minds Biosciences Closes its US$175 Million Public Offering	MT
01-09	Bright Minds Biosciences Closes $175.1 Million Stock Offering	MT
01-08	Bright Minds Biosciences Prices $175 Million Stock Offering	MT
01-08	Bright Minds Biosciences announces pricing of upsized US$175 million public offering of common stock at $90.00 per share	RE
01-06	Bright Minds Biosciences Launches US$100 Million Public Offering	MT
01-06	Bright Minds Biosciences Launches $100 Million Public Offering	MT
01-06	Bright Minds Biosciences Inc. Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies	CI
01-06	Bright Minds Biosciences Says Phase 2 Trial Results of BMB-101 Show 'Robust' Reduction in Seizure	MT
01-05	Bright Minds to announce topline results for BMB-101 phase 2 trial on Jan 6	RE
12-23	Bright Minds Biosciences Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
11-17	Bright Minds Biosciences Inc. Expands Scientific Advisory Board	CI
11-06	Bright Minds Biosciences Inc. Initiates New Prader-Willi Syndrome Program	CI
22/09/25	Bright Minds Biosciences Inc.(NasdaqCM:DRUG) added to S&P Global BMI Index	CI
05/09/25	Bright Minds Biosciences Enters Deal for $100 Million At-The-Market Offering	MT
04/09/25	Sector Update: Health Care Stocks Rise Late Afternoon	MT
04/09/25	Sector Update: Health Care Stocks Rise Thursday Afternoon	MT
04/09/25	Bright Minds Biosciences Announces BMB-201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model	CI
04/09/25	Bright Minds Says BMB-201 Outperforms Sumatriptan in Preclinical Vascular Headache Trial	MT
14/08/25	Bright Minds Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2025	CI
30/06/25	Bright Minds Biosciences Inc.(NasdaqCM:DRUG) added to Russell 3000 Growth Index	CI
30/06/25	Bright Minds Biosciences Inc.(NasdaqCM:DRUG) added to Russell 2000 Dynamic Index	CI
30/06/25	Bright Minds Biosciences Inc.(NasdaqCM:DRUG) added to Russell Small Cap Comp Growth Index	CI
30/06/25	Bright Minds Biosciences Inc.(NasdaqCM:DRUG) added to Russell Microcap Index	CI
30/06/25	Bright Minds Biosciences Inc.(NasdaqCM:DRUG) added to Russell 3000 Index	CI
30/06/25	Bright Minds Biosciences Inc.(NasdaqCM:DRUG) added to Russell Microcap Growth Index	CI

Chart Bright Minds Biosciences Inc.

Duration

Period

DRUG: Dynamic Chart

Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

Employees

Sector

Biotechnology & Medical Research

Calendar

02-17 - Q1 2026 Earnings Release (Projected)

More about the company